Globeimmune, Inc.

University of Colorado

University Technology Corporation

Apoplogic Pharmaceuticals, Inc.

Menogenix, Inc.

Richard C Duke

Alex Franzusoff

Donald Bellgrau

Thomas H King

Aurelia Haller

Cara C Wilson

David Apelian

Jaime F Modiano

Yingnian Lu

Jerome B Schaack

Debra M Duke

Victoria Kelley Hodson

The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of treatment for individuals selected as likely to benefit from anti-cancer therapy based on Fas expression levels.

Use of tumor Fas expression to determine response to anti-cancer therapy

The invention provides for compositions and methods of treating or ameliorating menopausal symptoms and/or symptoms associated with hormonal variations by administering granulocyte colony-stimulating factor (G-CSF). The invention also provides for compositions and methods of treating or ameliorating arthritis using G-CSF.

Methods of treating symptoms associated with menopause and hormonal variations with G-CSF

Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

Yeast-based therapeutic for chronic hepatitis C infection

Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables 'rescue' of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.

Immunotherapy for chronic hepatitis C virus infection

This invention discloses a novel method for propagation of viral vectors encoding proteins that induce apoptosis. The invention also discloses viral vectors produced by such methods and cells transfected with such vectors. Also disclosed are methods for suppressing T-lymphocyte-mediated graft rejection, for suppressing T-lymphocyte-mediated disease and for inducing apoptosis in cancer cells.

Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same

Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.

Yeast-antigen compositions and methods of using the same

The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.

Yeast-based vaccine for inducing an immune response

Yeast-antigen compositions methods of making the same

Yeast-dendritic cell vaccines and uses thereof

A method for inhibiting T-lymphocyte-mediated immune responses, including those directed against autologous and/or heterologous tissues, e.g., by a recipient mammal of a transplanted tissue, said method comprising providing the recipient mammal with Fas ligand. The Fas ligand may be provided to the recipient mammal by a variety of means, including by pump implantation or by transplantation of transgenic tissue expressing Fas ligand. Also provided is a method for diagnostic use of Fas ligand expression in improving transplantation success.

Growing community of inventors

Denver, CO, United States of America

Richard C Duke